Prof Benjamin Solomon
Honorary Conjoint Professorial Fellow
The Sir Peter MacCallum Department of Oncology
778 Scholarly works
20 Projects
HIGHLIGHTS
2026
Journal article
Final Biomarker and Efficacy Analyses of Lorlatinib in Patients With ALK-Positive Advanced NSCLC in a Phase 2 Study.
DOI: 10.1016/j.jtho.2026.1042022026
Journal article
Adjuvant alectinib versus chemotherapy in resected ALK-positive non-small-cell lung cancer (ALINA): health-related quality-of-life and safety outcomes from a randomised, open-label, phase 3 trial
DOI: 10.1016/S1470-2045(26)00283-42026
Journal article
Sovereignty and Survival: Understanding Lung Cancer Outcomes for Aboriginal and Torres Strait Islander People in Australia, a Case–Control Study
DOI: 10.5694/mja2.702782025
Research grants (ARC, NHMRC, MRFF)
Advancing Precision Medicine for Lung Cancer
2020
Journal article
Targeting platelets for improved outcome in KRAS-driven lung adenocarcinoma
DOI: 10.1038/s41388-020-1357-62020
Research Grant
PRedicting the Population Health Economic IMpact of Current and New CAncer Treatments (PRIMCAT)
2020
Research grants (ARC, NHMRC, MRFF)
Delivering Personalised Medicine for Lung Cancer
RECENT SCHOLARLY WORKS
2026
Journal article
SKYSCRAPER-01: Tiragolumab in Combination With Atezolizumab in Previously Untreated PD-L1–High, Locally Advanced, Unresectable or Metastatic Non–Small Cell Lung Cancer
DOI: 10.1200/JCO-25-027772026
Journal article
Lorlatinib versus crizotinib as first-line treatment for advanced ALK-positive non-small-cell lung cancer: 7-year update from the phase III CROWN study
DOI: 10.1016/j.annonc.2026.05.6922026
Journal article
Rilvegostomig for Metastatic Non-Small-Cell Lung Cancer: A First-In-Human Phase I/II Clinical Study.
DOI: 10.1158/1078-0432.CCR-26-03332026
Journal article
Real-world treatment sequencing and survival in ROS1-Rearranged NSCLC across evolving treatment eras: Findings from the AURORA multi-centre registry (AURORA-ROS1)
DOI: 10.1016/j.lungcan.2026.1095002026
Journal article
Adjuvant alectinib versus platinum-based chemotherapy in patients from Asia with completely resected ALK-positive non-small cell lung cancer (NSCLC): an exploratory subgroup analysis of ALINA including pharmacokinetics and safety in Japanese patients
DOI: 10.1016/j.ijlcan.2026.1000622026
Journal article
Bridging evidence and practice: international multidisciplinary consensus on non-metastatic NSCLC.
DOI: 10.1016/j.jtho.2026.1041112026
Journal article
PP01.08: Landscape of Genomic Mechanisms of Resistance to Selective RET Inhibitors in RET-Altered Solid Tumors: Analysis of the RETgistry Global Consortium
DOI: 10.1016/j.jtho.2026.104007
RECENT PROJECTS
2026
Research grants (ARC, NHMRC, MRFF)
A vaLue-based Person-Centric Enhanced Health Technology Assessment in CAncer Medicine (ALPACA)